Verition Fund Management LLC acquired a new position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 97,200 shares of the company's stock, valued at approximately $792,000. Verition Fund Management LLC owned about 0.17% of Ginkgo Bioworks as of its most recent SEC filing.
Several other hedge funds also recently modified their holdings of DNA. AQR Capital Management LLC purchased a new position in Ginkgo Bioworks during the 2nd quarter worth $3,391,000. Monaco Asset Management SAM bought a new stake in Ginkgo Bioworks in the 2nd quarter worth about $3,276,000. Renaissance Technologies LLC purchased a new stake in Ginkgo Bioworks in the 2nd quarter valued at about $2,128,000. Cetera Investment Advisers boosted its stake in shares of Ginkgo Bioworks by 2,683.7% in the 1st quarter. Cetera Investment Advisers now owns 2,264,107 shares of the company's stock worth $2,626,000 after buying an additional 2,182,773 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Ginkgo Bioworks in the second quarter valued at approximately $312,000. Hedge funds and other institutional investors own 78.63% of the company's stock.
Ginkgo Bioworks Price Performance
Shares of NYSE DNA traded up $0.36 during trading on Tuesday, reaching $11.06. 1,102,229 shares of the stock traded hands, compared to its average volume of 1,160,538. The firm has a 50-day moving average of $8.28. Ginkgo Bioworks Holdings, Inc. has a 52-week low of $5.26 and a 52-week high of $75.20. The stock has a market cap of $635.43 million, a PE ratio of -0.85 and a beta of 1.17.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on the company. TD Cowen upped their price objective on Ginkgo Bioworks from $3.00 to $10.00 and gave the company a "buy" rating in a research note on Friday, September 20th. BTIG Research lifted their price objective on shares of Ginkgo Bioworks from $0.20 to $7.00 and gave the stock a "sell" rating in a research report on Friday, August 23rd. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $4.58.
Get Our Latest Stock Report on DNA
About Ginkgo Bioworks
(
Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Further Reading
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
